positive
2h agoLarge scale capital rotation flows into healthcare and biotech AI pipeline

Hippocratic AI secured one hundred twenty six million dollars in Series C funding, taking cumulative capital above two hundred thirty million dollars. Beacon Software closed a two hundred fifty million dollar Series B round, lifting its total to around three hundred thirty five million dollars. Braveheart Bio raised one hundred eighty five million dollars in Series A.
Investors say the current wave shows disciplined late cycle risk capital is concentrating into high scientific moats and defensible regulatory advantage vectors versus broad speculative AI infrastructure exposure.
Explore:Mutual Fund Screening
positive
2h agoLarge scale capital rotation flows into healthcare and biotech AI pipeline

Hippocratic AI secured one hundred twenty six million dollars in Series C funding, taking cumulative capital above two hundred thirty million dollars. Beacon Software closed a two hundred fifty million dollar Series B round, lifting its total to around three hundred thirty five million dollars. Braveheart Bio raised one hundred eighty five million dollars in Series A.
Investors say the current wave shows disciplined late cycle risk capital is concentrating into high scientific moats and defensible regulatory advantage vectors versus broad speculative AI infrastructure exposure.
about 2 hours ago
1 min read
84 words

Hippocratic AI, Beacon Software and Braveheart Bio raised over five hundred sixty million dollars combined, signalling selective investor preference for regulatory protected healthcare and biotech AI.
Hippocratic AI secured one hundred twenty six million dollars in Series C funding, taking cumulative capital above two hundred thirty million dollars. Beacon Software closed a two hundred fifty million dollar Series B round, lifting its total to around three hundred thirty five million dollars. Braveheart Bio raised one hundred eighty five million dollars in Series A.
Investors say the current wave shows disciplined late cycle risk capital is concentrating into high scientific moats and defensible regulatory advantage vectors versus broad speculative AI infrastructure exposure.

Hippocratic AI secured one hundred twenty six million dollars in Series C funding, taking cumulative capital above two hundred thirty million dollars. Beacon Software closed a two hundred fifty million dollar Series B round, lifting its total to around three hundred thirty five million dollars. Braveheart Bio raised one hundred eighty five million dollars in Series A.
Investors say the current wave shows disciplined late cycle risk capital is concentrating into high scientific moats and defensible regulatory advantage vectors versus broad speculative AI infrastructure exposure.
Companies:
Hippocratic AI
Beacon Software
Braveheart Bio
Tags:
startups
funding
startups
funding
ai
healthcare
biotech
Nov 8, 2025 • 11:43 IST